Antibody-drug conjugates (ADCs) combine the targeting specificity of monoclonal antibodies with potent cytotoxic payloads, but their activity depends on multiple interconnected cellular processes. Internalization, intracellular trafficking, payload release, and Fc-mediated activity can each influence therapeutic response, making it challenging to determine which mechanisms drive a candidate’s efficacy.
In this webinar, Jane Lamerdin will discuss how integrated cell-based assays can characterize ADC mechanisms of action and generate functional insights to support candidate prioritization and preclinical development.
Topics to be covered:
- Characterizing ADC internalization and lysosomal trafficking using multiparametric cell-based assays
- Distinguishing payload-mediated cytotoxicity from Fc-mediated effects
- Applying functional data to compare and prioritize ADC candidates
- Using mechanism-resolved characterization to inform preclinical optimization and development
Thursday, November 12th 2026 | 11:00 AM – 12:00 PM Eastern Time
This webinar will be available to view live and on demand.
Speaker
Jane Lamerdin, PhD
Vice President of Research and Development
Eurofins DiscoverX
